Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FABP6 | P51161 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384648 | 1.00 | TSHR (0.44) | TSHRNPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL18384657 | 0.81 | PDE4A (0.42) | HPGDNPSR1MAPTALDH1A1 | |
| SCHEMBL18384647 | 0.81 | PDE4A (0.47) | L3MBTL1HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL18384644 | 0.81 | PDE4A (0.42) | HPGDNPSR1MAPTALDH1A1 | |
| SCHEMBL18384660 | 0.81 | PDE4A (0.47) | L3MBTL1HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL18384634 | 0.80 | HTT (0.44) | TSHRNPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL18384667 | 0.80 | HTT (0.44) | TSHRNPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL18384532 | 0.80 | HPGD (0.48) | TSHRNPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL18384595 | 0.80 | HPGD (0.48) | TSHRNPC1RAB9AL3MBTL1HPGD | |
| SCHEMBL18384645 | 0.79 | KDM4E (0.40) | HPGDMAPTALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | TSHR 2047/4885NPC1 1215/4885RAB9A 347/4885 |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | TSHR 2047/4885NPC1 1215/4885RAB9A 347/4885 |
| US-10934309-B2 | Tricyclic quinone derivative | NQO1, NQO2, SQOR | TSHR 2094/4885NPC1 1206/4885RAB9A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.